Current read
Clinical traction from 27 study records, 43 active source records, 3 rapid briefs, and 0 timeline events. Evidence maturity is 78/100, human translation signal is 75/100, and frontier activity is moderate (50/100). Frontier activity means research movement, not settled human proof.
This lane has stronger human/clinical support, but still needs bounded claims.
Commercial bias penalty: 64/100. Confidence: 78/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Cognitive health, brain imaging, neurodegeneration, sleep, movement, and claims that compress endpoints. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 96/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
Sleep and exercise interventions, neurodegeneration trials, brain-imaging endpoint discipline.
What would move this row up?
Current bottleneck
Replication, durability, and sharper endpoint evidence.
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Durable cognitive or daily-function outcomes rather than imaging-only signals.
Durable cognitive or daily-function outcomes rather than imaging-only signals.
Longer follow-up in age-relevant and neurodegeneration-relevant populations.
Longer follow-up in age-relevant and neurodegeneration-relevant populations.
Evidence that would change the map
- Raise evidence maturity from 78/100 with better controlled studies or stronger replication.
- Raise human translation from 96/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not turn imaging signals into brain-age reversal.
- Do not call early neurodegeneration trials cures without functional evidence.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
The First Huntington's Patient Received Neural Stem Cells in a First-in-Human Trial
UCI Health treated the first patient in REGEN4HD, moving hNSC-01 from preclinical promise into human safety testing for Huntington's disease.
Why now
First-patient dosing moves a neural stem cell strategy for Huntington's disease from preclinical story to monitored human safety trial.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 27, 2026
The FDA May Be Opening a More Flexible Path for Rare-Disease Gene Therapies
A new FDA draft guidance and recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 24, 2026
EU Approved Cenrifki for a Difficult-to-Treat Form of Progressive MS
Sanofi's Cenrifki/tolebrutinib was approved in the EU for secondary progressive multiple sclerosis without recent relapses, where disability can worsen even without flare-ups.
Why now
The approval targets disability progression in a form of MS where obvious relapses may have stopped.
- Overclaim risk
- medium
- Primary source
- Trade news
- Published
- Jun 24, 2026
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Does Cannabis Shrink Your Brain?
A viral claim turns cannabis brain research into a one-line shrinkage scare. The evidence is messier: blood flow, activation, volume, cognition, age, dose, and heavy-use patterns are not interchangeable.
VV Signal Score
58
Early or context-dependent
- Sources
- 10
- Studies
- 7
- Claims
- 7
Mouth Taping: Nasal-Breathing Hack or Sleep-Apnea Red Flag?
Mouth taping looks ridiculous enough to go viral and plausible enough to sell. The evidence is narrow, the risks are underplayed, and snoring deserves more respect.
VV Signal Score
47
Mixed signal
- Sources
- 11
- Studies
- 11
- Claims
- 10
Calories Are the Accounting System, Not the Whole Metabolic Story
Weight loss requires an energy deficit, but calories alone do not explain appetite, metabolism, food environment, hormones, lean mass, sleep, medications, or long-term maintenance.
VV Signal Score
83
Strong signal
- Sources
- 13
- Studies
- 10
- Claims
- 8
Sleep Is More Than Hours—and Less Certain Than the Headlines
Poor sleep tracks with inflammation, chronic disease, and mortality risk. The signal is meaningful, but the strongest outcome evidence is observational—not proof that a better sleep score adds years to life.
VV Signal Score
65
Promising signal
- Sources
- 6
- Studies
- 6
- Claims
- 6
Creatine Beyond Muscle: Cheap Supplement or Overextended Brain Hack?
Creatine is one of the rare supplements where the baseline evidence is not flimsy. That makes the overclaim risk more interesting: strong sports-nutrition evidence is now being stretched into cognition, depression, aging, women’s health, sleep deprivation, and neuroprotection.
VV Signal Score
78
Promising signal
- Sources
- 7
- Studies
- 6
- Claims
- 4
Red Light Therapy: Mitochondrial Medicine or Expensive Lamp Culture?
Red and near-infrared light claims range from skin and pain to hair growth, testosterone, thyroid, fat loss, and brain performance. The evidence is not one category. Dose, wavelength, distance, tissue depth, and outcome decide whether the claim is medicine, beauty tech, rehab tool, or expensive lamp culture.
VV Signal Score
59
Early or context-dependent
- Sources
- 6
- Studies
- 6
- Claims
- 4
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
sleep: Sleep restriction can affect appetite-regulating signals and hunger, making
Sleep restriction can affect appetite-regulating signals and hunger, making sleep relevant to weight-management behavior and adherence.
sleep: Sleep duration is associated with all-cause mortality in a
Sleep duration is associated with all-cause mortality in a U-shaped pattern in prospective cohort meta-analysis, with both short and long sleep linked to higher mortality risk versus roughly 7 hours, but causality is not proven.
sleep: Objective sleep regularity is associated with all-cause and cause-specific
Objective sleep regularity is associated with all-cause and cause-specific mortality risk, and may capture a health-relevant sleep dimension that average duration alone misses.
sleep: Sleep disturbance has biologically plausible links to inflammatory and
Sleep disturbance has biologically plausible links to inflammatory and immune dysregulation through cytokine, neuroendocrine, autonomic, and antiviral-response pathways, but inflammation mediation between sleep and mortality is not settled.
sleep: Sleep duration, sleep quality, and sleep regularity are distinct
Sleep duration, sleep quality, and sleep regularity are distinct dimensions of sleep health, and consumer claims should avoid treating hours slept as the whole sleep signal.
sleep: Longitudinal commercial wearable sleep data can reveal associations between
Longitudinal commercial wearable sleep data can reveal associations between sleep duration, irregularity, sleep stages, and chronic disease incidence, but wearable sleep scores should not be treated as clinical-grade diagnosis.